Becton Dickinson & Co. recalled 4,283 BD Phoenix M50 Instruments on September 23, 2025. Unauthorized access to service credentials raises risks to data confidentiality and integrity. The recall affects devices distributed worldwide, including the U.S., Canada, and several countries across Europe and Asia.
Product service credentials used by some BD technical support teams to access certain BD products were accessed by an unauthorized actor. Until these product service credentials are updated, there is a risk of unauthorized access that may impact the confidentiality, integrity and/or availability of the relevant products and associated data.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Becton Dickinson & Co. or your healthcare provider for instructions. Notification method: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
The recalled models are BD Phoenix M50 Automated Microbiology Systems with catalog numbers 443624 and 44362409. These devices were distributed worldwide, including the U.S., Guam, and Puerto Rico. They were sold through multiple retailers.
The recall stems from unauthorized access to product service credentials. This breach could potentially compromise the confidentiality, integrity, and availability of the products and associated data.
No specific incidents of injury or data breach have been reported at this time. The risk remains due to potential unauthorized access.
Stop using the BD Phoenix M50 Instrument immediately. Contact Becton Dickinson & Co. or your healthcare provider for further instructions and follow the recall procedures provided.
For more information, call Becton Dickinson & Co. or visit their website. Additional details can be found at https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=Z-0239-2026.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.